Newtown, Pennsylvania-based Onconova Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, has named James J Marino to its board of directors. Mr Marino was a partner at the global law firm of Dechert for 28 years where he was managing partner of the Princeton office. During this period, he advised numerous leading life science companies in connection with financings, acquisitions and strategic alliances. He served as the outside counsel for Onconova from its inception through and including its initial public offering. Previously, he was on the board of Pharmacopeia Drug Discovery from 2000-2006 and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital.
Onconova appoints James Marino board
Newtown, Pennsylvania-based Onconova Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, has named James J Marino to its board of directors. Mr Marino was a partner at the global law firm of Dechert for 28 years where he was managing partner of the Princeton office. During this period, he advised numerous leading life science companies in connection with financings, acquisitions and strategic alliances. He served as the outside counsel for Onconova from its inception through and including its initial public offering. Previously, he was on the board of Pharmacopeia Drug Discovery from 2000-2006 and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson University Hospital.
More from Anticancer
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
More from Therapy Areas
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
The UK giant is forecasting peak sales of $5bn plus